Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC trimmed its stake in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 11.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 376,968 shares of the biopharmaceutical company's stock after selling 47,651 shares during the period. Nuveen Asset Management LLC owned 0.24% of Novavax worth $3,031,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Deep Track Capital LP purchased a new stake in Novavax in the fourth quarter worth about $16,080,000. BNP Paribas Financial Markets boosted its holdings in shares of Novavax by 289.0% in the fourth quarter. BNP Paribas Financial Markets now owns 556,832 shares of the biopharmaceutical company's stock worth $4,477,000 after buying an additional 413,676 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Novavax in the 4th quarter worth $2,761,000. ExodusPoint Capital Management LP purchased a new position in shares of Novavax during the 4th quarter valued at about $2,687,000. Finally, Barclays PLC boosted its holdings in Novavax by 73.9% in the 3rd quarter. Barclays PLC now owns 709,579 shares of the biopharmaceutical company's stock worth $8,961,000 after buying an additional 301,627 shares during the period. 53.04% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on NVAX. JPMorgan Chase & Co. dropped their target price on shares of Novavax from $9.00 to $7.00 and set an "underweight" rating for the company in a research report on Friday, May 9th. BTIG Research began coverage on shares of Novavax in a research note on Friday, February 28th. They issued a "buy" rating and a $19.00 target price on the stock. TD Cowen upgraded Novavax to a "hold" rating in a report on Thursday, February 27th. Finally, B. Riley restated a "buy" rating on shares of Novavax in a research note on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $19.00.

Novavax Price Performance

NASDAQ NVAX traded up $0.46 during midday trading on Friday, hitting $7.45. 7,414,868 shares of the company traded hands, compared to its average volume of 6,764,899. The company has a market cap of $1.21 billion, a PE ratio of -3.30, a price-to-earnings-growth ratio of 2.85 and a beta of 2.80. Novavax, Inc. has a 52 week low of $5.01 and a 52 week high of $19.50. The company's 50-day simple moving average is $6.61 and its 200-day simple moving average is $7.76.

Novavax (NASDAQ:NVAX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 EPS for the quarter, beating analysts' consensus estimates of $0.71 by $2.22. The firm had revenue of $666.66 million for the quarter, compared to analysts' expectations of $204.08 million. The company's revenue was up 610.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.05) EPS. On average, research analysts predict that Novavax, Inc. will post -1.46 earnings per share for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.